References chapter 29 Behçet syndrome - EULAR

1 EULAR Textbook on Rheumatic Diseases References chapter 29 Beh et syndrome Direskeneli H. Autoimmunity vs autoinflammation in Beh et s disease : do we oversimplify a complex disorder? Rheumatology (Oxford) 2006;45:1461 5 Espinosa G, Font J, Tassies D, et al. Vascular involvement in Beh et s disease : relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med 2002;112:37 43. Hamuryudan V, Er T, Seyahi E, et al. Pulmonary artery aneurysms in Beh et syndrome . Am J Med 2004;117:867 70. Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Beh et s syndrome : effects on long-term prognosis. Arthritis Rheum 1997;40:769 74. Kotter I, Gunaydin I, Zierhut M, et al. The use of interferon alpha in Beh et disease : review of the literature.

2 Semin Arthritis Rheum 2004;33:320 35. Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Beh et syndrome : a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003;82:60 76. Yazici H, Fresko I, Yurdakul S. Beh et s syndrome : disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol 2007;3:148 55. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behcet s syndrome . N Engl J Med. 1990;322:281 5. Remmers EF, Cosan F, Kirino Y et al. Genome wide association studies identifies variants in the MHC Class I, IL 10, and IL23R-IL12RB2 regions associated with Behcet s disease . Nat Genet 2010:42:698-702 Mizuki N, Meguro A, Ota M et al.

3 Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Beh et's disease susceptibility loci. Nat Genet. 2010; 42(8):703-6. Akman-Demir G, Saip S, Siva A. Beh et s disease . Curr Treat Options Neurol 2011;13(3):290-310. Ideguchi H, Suda A, Takeno M et al. Behcet disease : evolution of clinical manifestations. Medicine (Baltimore) 2011;90(2):125-132. Relapsing polychondritis Buckley LM, Ades PA. Progressive aortic valve inflammation occurring despite apparent remission of relapsing polychondritis. Arthritis Rheum 1992;35:812 14. EULAR Textbook on Rheumatic Diseases Chang-Miller A, Okamura M, Torres VE, et al. Renal involvement in relapsing polychondritis. Medicine 1987;66:202 17. Frances C, el Rassi R, Laporte JL, et al. Dermatologic manifestations of relapsing polychondritis.

4 A study of 200 cases at a single center. Medicine (Baltimore) 2001;80:173 9. Hanslik T, Wechsler B, Piette J-C, et al. Central nervous system involvement in relapsing polychondritis. Clin Exp Rheumatol 1994;12:539 41. Kent PD, Michet CJ Jr, Luthra HS. Relapsing polychondritis. Curr Opin Rheumatol 2004;16:56 61. McAdam LP, O Hanlan MA, Bluestone R, et al. Relapsing polychondritis: prospective study of 23 patients and a review of the literature. Medicine 1976;55:193 215. Mpofu S, Estrach C, Curtis J, et al. Treatment of respiratory complications in recalcitrant relapsing polychondritis with infliximab. Rheumatology (Oxford) 2003;42:1117 8. Saadoun D, Deslandre CJ, Allanore Y, et al. Sustained response to infliximab in 2 patients with refractory relapsing polychondritis.

5 J Rheumatol 2003;30:1394 5. Sundaram MBM, Rajput AH. Nervous system complications of relapsing polychondritis. Neurology 1983;33:513 15. Zeuner M, Straub RH, Rauh G, et al. Relapsing polychondritis: clinical and immunogenetic analysis of 62 patients. J Rheumatol 1997;24:96 101. Eye involvement Harper SL, Foster CS. The ocular manifestations of rheumatoid disease . Int Ophthalmol Clin 1998;38:1 9. Lyons JL, Rosenbaum JT. Uveitis associated with inflammatory bowel disease compared with uveitis associated with spondylarthropathy. Arch Ophthalmol 1997;115:61 4. Marmor ME, Carr RE, Easterbrook M, et al. American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology.

6 Ophthalmology 2002;109:1377 82. Patel SJ, Lundy DC. Ocular manifestations of autoimmune disease . Am Fam Physician 2002;66:991 8. Perez VL, Chavala SH, Ahmed M, et al. Ocular manifestations and concepts of systemic vasculitides. Surv Ophthalmol 2004;49:399 418. Rucker CW, Ferguson RH. Ocular manifestations of relapsing polychondritis. Arch Ophthalmol 1965;73:46 50. Soo MP, Chow SK, Tan CT, et al. The spectrum of eye involvement in patients with systemic lupus erythematodes without ocular symptoms. Lupus 2000;9:511 4. EULAR Textbook on Rheumatic Diseases Zierhut M, St biger N, Deuter CME, et al. Beh et s disease . In: Pleyer U, Mondino B, eds. Essentials in ophthalmology: uveitis and immunological disorders. Berlin, Heidelberg: Springer, 2005:173 200.

7 New References in text (Behcet and Relapsing Polychondritis): 1) Mahr A, Belarbi L, Wechler B et al. Population-based prevalence study of Beh et's disease :differences by ethnic origin and low variation by age at immigration. Arthritis Rheum 2008:58:3951-3959. 2) Seyahi E, Tahir Turanl E, Mangan MS et al. The prevalence of Beh et s syndrome , familial Mediterranean fever, HLA-B51 and MEVF gene mutations among ethnic Armenians living in Istanbul, Turkey. Clin Exp Rheumatol 2010; 28(4 suppl 60): S67-75. 3) Ugurlu S, Seyahi E, Yazici H. Prevalence of angina, myocardial infarction and intermittent claudication assessed by Rose Questionnaire among patients with Behcet's syndrome . Rheumatology (Oxford). 2008;47:472-5. 4) Cheon JH, Celik AF, Ho Kim W. Behcet s disease : Gastrointestinal involvement.

8 Behcet s syndrome , eds Yazici Y and Yazici H, Springer, 2010:165-188. 5) Fresko I, Soy M, Hamuryudan V et al. Genetic anticipation in Behcet s syndrome . Ann Rheum Dis 1998:57:45-48. 6) de Menthon M, Lavalley MP, Maldini C et al. HLA-B51/B5 and the risk of Beh et's disease : a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum 2009:61:1287-1296. 7) Remmers EF, Cosan F, Kirino Y et al. Genome wide association studies identifies variants in the MHC Class I, IL 10, and IL23R-IL12RB2 regions associated with Behcet s disease . Nat Genet 2010:42:698-702. 8) Saruhan-Direskeneli G, Uyar FA, Cefle A et al. Expression of KIR and C-type lectin receptors in Behcet's disease . Rheumatology (Oxford) 2004:43:423-427. 9) Mizuki N, Meguro A, Tohnai I et al.

9 Association of Major Histocompatibility Complex Class I Chain-Related Gene A and HLA-B Alleles with Beh et's disease in Turkey. Jpn J Ophthalmol 2007:51:431-436. 10) Gul A, Ohno S. Genetics of Behcet s disease . Behcet s syndrome , eds Yazici Y and Yazici H, Springer, 2010:265-276. 11) Frassanito MA, Dammacco R, Cafforio P et al. Th1 polarization of the immune response in Beh et's disease : a putative pathogenetic role of interleukin-12. Arthritis Rheum 1999:42:1967-1974. 12) Imamura Y, Kurokawa MS, Yoshikawa H et al. Involvement of Th1 cells and heat shock protein 60 in the pathogenesis of intestinal Behcet's disease . Clin Exp Immunol 2005:139:371-378. 13) Hamzaoui K, Hamzaoui A, Guemira F et al. Cytokine profile in Beh et's disease patients. Relationship with disease activity.

10 Scand J Rheumatol. 2002:31:205-210. 14) Neves FS, Carrasco S, Goldenstein-Schainberg C et al. Neutrophil hyperchemotaxis in Beh et's disease : a possible role for monocytes orchestrating bacterial-induced innate immune responses. Clin Rheumatol. 2009:28:1403-1410. 15) Freysdottir J, Hussain L, Farmer et al. Diversity of gammadelta T cells in patients with Behcet's disease is indicative of polyclonal activation. Oral Dis. 2006;12:271-277. 16) Hatemi G, Fresko I, Tascilar K et al. Increased enthesopathy among Beh et's syndrome patients with acne and arthritis: an ultrasonography study. Arthritis Rheum. 2008;58:1539-45. 17) Kaburaki T, Araki F, Takamoto M et al. Best-corrected visual acuity and frequency of ocular attacks during the initial 10 years in patients with Beh et's disease .